Skin Reactivity In Patients Research Articles

Tobacco Use and Skin Reactivity in Patients With Percutaneous Auditory Osseointegrated Implants.

To determine if there is an association between tobacco use and the development of postoperative skin reactions in patients undergoing percutaneous osseointegrated auditory implant (pOAI) surgery. Single surgeon retrospective cohort study. Academic medical center. Retrospective chart review was performed on all patients who underwent pOAI. Smoking status (current and former users versus never-users) was recorded as were numerous demographic and surgical variables. The primary outcome measure was skin reactivity as measured by Holgers score. Secondary outcomes studied included total number of problem visits, minor interventions, and major interventions. 126 patients, 73 with no tobacco history (NT) and 53 with a positive smoking tobacco history (T) underwent pOAI surgery in this study. The T group was found to have higher rates of first postoperative visit soft tissue reactions compared with the NT group (24.5% versus 6.8%, p 1/4 0.011, odds ratio [OR] 4.42, 95% confidence interval [CI]: 1.5, 13.3), but not at long-term follow-up. When former smokers were eliminated from analysis, differences were also found at long- term follow-up (40.9% versus 19.2%, p 1/4 0.037, OR 2.92, 95% CI [1.0 - 8.1]). There were no differences in total number of problem visits or total number of minor or major interventions. Patients with a history of tobacco use have a significantly higher rates of skin reactivity compared with patients without, though smoking cessation may partially mitigate long-term risks. Surgeons should be aware of the risks of early skin reactivity and should counsel patients accordingly.

MRGPRX2 Activation Causes Increased Skin Reactivity in Patients with Chronic Spontaneous Urticaria

We present heightened skin reactivity in vivo to two MRGPRX2 drug ligands in patients with chronic spontaneous urticaria. Selectivity for the MRGPRX2 pathway by drug ligands was demonstrated by the loss of drug activation in MRGPRX2-KO LAD2 cells.

Do Postoperative Antibiotics Improve Skin Reactivity Following Percutaneous Auditory Osseointegrated Implant Placement?

To determine if the routine use of postoperative antibiotics following percutaneous auditory osseointegrated implant placement reduces skin reactivity. Retrospective matched case-controlled series. Tertiary academic medical center. A total of 44 patients who underwent percutaneous auditory osseointegrated implant placement were divided into those who received 5 days of postoperative antibiotics (AB) and those who received no antibiotics (NAB). All surgery was performed using the same surgical technique (Minimally Invasive Ponto Surgery). Variables recorded included patient demographics, Holgers skin reaction score, complications, and need for further intervention. A total of 23 patients received prophylactic postoperative antibiotics (AB) while 21 patients did not (NAB). At the first postoperative visit (AB 12.7 d versus NAB 12.3 d, p = 0.9) there were no differences in average Holgers score (AB 0.3 ± 0.7 versus NAB 0.2 ± 0.5, p = 0.27). The odds ratio for skin reactivity at the first visit was 0.11 (95% CI 0.01-2.32). There were also no statistical differences in Holgers score (AB 0.05 ± 0.2 versus NAB 0.1 ± 0.3, p = 0.25) at most recent followup visit (AB mean 97.5 d versus NAB 102.8 d, p = 0.84). The odds ratio for skin reactivity at the most recent visit was 0.16 (95% CI 0.01-3.64). The use of postoperative antibiotics does not appear to confer significant difference in skin reactivity in patients receiving percutaneous osseointegrated auditory implants. Such findings support the theory that skin reactivity, when it does occur, may not be an infectious-mediated process.

Autologous intradermal skin tests in women with Hashimoto’s thyroiditis

IntroductionIn a large proportion of patients with chronic urticaria, a coexisting autoimmune type of Hashimoto's thyroiditis is being diagnosed. An intradermal test with autologous serum has been generally considered as a screening procedure indicating the presence of triggering autoimmune inflammatory factors in the sera of patients with urticaria. These factors could be possibly involved in the pathogenesis of the disease. Now, it seems that in order to complete the screening diagnostic procedures of autoimmune component in patients with spontaneous chronic urticaria, intradermal tests with autologous plasma could be also useful.AimTo assess skin reactivity in patients suffering from the autoimmune type of Hashimoto's thyroiditis with serum and plasma intradermal tests.Material and methodsThirty-five female patients with Hashimoto's thyroiditis aged 23-78 years were recruited for our study. The control group consisted of 20 healthy volunteers with a negative history and no signs or symptoms of any thyroid as well as autoimmune diseases. Intradermal tests with autologous plasma, serum and with 0.9% NaCl (negative control) were performed.ResultsFive patients with the autoimmune type of Hashimoto's thyroiditis presented positive results of the autologous serum test (14.2%) while positive results of the autologous plasma test were obtained in 2 cases (5.7%). It seems to be important that subjects with positive results of intradermal tests have not been treated with L-thyroxine. In the case of healthy volunteers results of our diagnostic procedures were negative.ConclusionsThis study suggests that thyroid suppression by L-thyroxine can result in clinical remission of urticaria symptoms.

Effect of cetirinax on the skin reactivity in patients with chronic urticaria

Effect of cetirinax on the skin reactivity in patients with chronic urticaria

No increased skin reactivity in subjects with allergic rhinitis during the active phase of the disease.

Data on skin reactivity in patients with respiratory atopy without atopic dermatitis are scarce and controversial. Our purpose was to assess whether skin reactivity in patients with seasonal allergic rhinitis varies according to the phase of the disease and the possible release of inflammatory mediators acting on the skin during the pollen season. The volar forearm skin of eleven patients with seasonal allergic rhinitis without atopic dermatitis was challenged with a single exposure to sodium lauryl sulfate. The skin response was evaluated instrumentally over 72 h by transepidermal water loss, capacitance and echogenicity measurements for the assessment of skin damage and the inflammatory response. Tests were performed in winter and repeated in spring in seasonal allergic rhinitis patients, when they showed respiratory symptoms. Fifteen subjects with atopic dermatitis underwent the same experimental procedure in winter as a control population. Baseline and postexposure values were similar both in winter and in spring in seasonal allergic rhinitis patients. After sodium lauryl sulfate challenge, atopic dermatitis patients showed a higher degree of skin barrier damage and inflammation compared to patients with seasonal allergic rhinitis. These findings suggest that subjects with seasonal allergic rhinitis without atopic dermatitis have normal epidermal barrier function and normal skin reactivity during both the inactive and the active phase of the disease. Inflammatory mediators possibly released by mucous membranes during active allergic rhinitis do not influence skin barrier function.

Skin reactivity in patients with cancer. Impaired delayed hypersensitivity or faulty inflammatory response?

DEPRESSION of the delayed hypersensitivity response in patients with advanced cancer has been observed by a number of investigators.1 2 3 4 The chemical hapten 2,4-dinitrochlorobenzene (DNCB) has been used widely for studies of such patients. The response can be quantitated, and almost all normal persons can be sensitized2 , 5; in addition, use of DNCB eliminates the problem of determining whether the patient has been exposed to any of the commonly used skin-test antigens. Furthermore, the majority of patients reacting to common antigens also react to DNCB.2 A correlation between reactivity to DNCB and prognosis in patients with cancer led Eilber and Morton . . .